Scotiabank initiated coverage on Agios Pharma
$AGIO
Biotechnology: Pharmaceutical Preparations
Health Care
Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/10/2024 | $51.00 | Outperform | Raymond James |
| 9/27/2024 | $60.00 → $56.00 | Outperform → Market Perform | Leerink Partners |
| 2/8/2024 | Overweight | Cantor Fitzgerald | |
| 2/3/2023 | $41.00 | Overweight | Piper Sandler |
| 11/17/2022 | $17.00 → $32.00 | Sell → Neutral | Goldman |
| 7/27/2022 | $33.00 | Mkt Perform → Outperform | SVB Leerink |
| 3/7/2022 | $37.00 → $23.00 | Sell | Goldman Sachs |
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
Agios Pharmaceuticals (NASDAQ:AGIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.25, a high estimate
Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia in a plenary session (abstract #S104) at the European Hematology Association 2024 (EHA2024) Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain. In a related poster presentation (abstract #P1529), the company presented additional data from the ENERGIZE study highlighting clinically meaningful improvements in health-related quality of life measures and patient-reported
– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and
– Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. "Agios is dedicated to cultivating a diverse board that is focused on the company's long-term value creation for patients and shareholders. As such, we are thrilled to welcome Jeff, whose nearly 30-year track record of driving profitab
EMERYVILLE, Calif., April 12, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment of Dr.Lewis Cantley, Dr. Hope Rugo, and Josep Tabernero to the company's Scientific Advisory Board (SAB). Totus has created the first biosearch technology that scans, maps, and decodes effective new drugs thousands of times faster than traditional drug discovery processes. To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform
Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00
Leerink Partners downgraded Agios Pharma from Outperform to Market Perform and set a new price target of $56.00 from $60.00 previously
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabo
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in pyr
– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYND® (Mitapivat) Net Revenue of $8.6 Million in Q2; Cash, Cash Equivalents and Marketable Securities of $645.3 Million as of June 30, 2024 – CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWS
10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity
Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted Onsite on Monday, December 9 – CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on mitapivat and tebapivat (AG-946), the company
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval of Vorasidenib – – Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS – – PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024 – CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabo
– Topline Data from 52-week Phase 3 Study Expected in Late 2025 – CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that enrollment is complete for the Phase 3 RISE UP study. This global, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of mitapivat, an oral, small molecule PK activator, in sickle cell disease patients who are 16 years of age or older. Agios expects to report topline results from this 52-week Phase 3 study in late 2025. Sickle cell disease is an inherited, lifelong